Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

PURPOSE: We assessed the safety and antitumor activity of avelumab, a fully human anti–programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. METHODS: In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressin...

Descripción completa

Detalles Bibliográficos
Autores principales: Apolo, Andrea B., Infante, Jeffrey R., Balmanoukian, Ani, Patel, Manish R., Wang, Ding, Kelly, Karen, Mega, Anthony E., Britten, Carolyn D., Ravaud, Alain, Mita, Alain C., Safran, Howard, Stinchcombe, Thomas E., Srdanov, Marko, Gelb, Arnold B., Schlichting, Michael, Chin, Kevin, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493051/
https://www.ncbi.nlm.nih.gov/pubmed/28375787
http://dx.doi.org/10.1200/JCO.2016.71.6795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493051/
https://www.ncbi.nlm.nih.gov/pubmed/28375787
http://dx.doi.org/10.1200/JCO.2016.71.6795

Ejemplares similares